What is the recommended osteoporosis treatment for a 73‑year‑old postmenopausal woman?

Osteoporosis Treatment for a 73-Year-Old Female

Start with oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) as first-line pharmacologic therapy, combined with calcium 1,200 mg daily and vitamin D 800 IU daily, plus weight-bearing exercise and fall prevention strategies. 1, 2

Diagnostic Confirmation

Before initiating treatment, confirm osteoporosis diagnosis if not already done:

• Perform DXA scanning of hip and spine if not completed within the past 2 years 1
• Osteoporosis is diagnosed by T-score ≤ -2.5 or presence of a fragility fracture 1, 3
• At age 73, she falls within the routine screening age (≥65 years for all postmenopausal women) 1

First-Line Pharmacologic Treatment

Bisphosphonates are the recommended initial therapy based on the strongest evidence for fracture reduction and cost-effectiveness 1, 2:

Specific Bisphosphonate Options:

• Alendronate 70 mg orally once weekly (generic available, most cost-effective) 1
• Risedronate 35 mg orally once weekly (alternative if alendronate not tolerated) 1
• Zoledronic acid 5 mg IV annually (if oral bisphosphonates contraindicated or not tolerated) 1

Bisphosphonate Administration Requirements:

• Take on empty stomach with full glass of water 1
• Remain upright (standing or sitting) for at least 30 minutes after dosing 1
• Contraindicated if: esophageal abnormalities, inability to stand/sit upright for 30 minutes, or hypocalcemia 1

Expected Benefits:

• Reduce vertebral fractures by approximately 52 per 1,000 person-years 3
• Reduce hip fractures by approximately 6 per 1,000 person-years 3

Essential Concurrent Non-Pharmacologic Interventions

Every patient requires these foundational measures 1, 3:

• Calcium supplementation: 1,200 mg daily (dietary plus supplements) 1, 3
• Vitamin D supplementation: 800 IU daily (target serum level ≥20 ng/mL) 1, 3
• Weight-bearing exercise: Regular walking, resistance training (squats, push-ups) 3
• Balance exercises: Heel raises, standing on one foot to prevent falls 3
• Smoking cessation if applicable 1, 4
• Alcohol moderation: Limit to <3 drinks daily 1, 4

Alternative Pharmacologic Options

If bisphosphonates are contraindicated or not tolerated 1:

Denosumab (Prolia):

• 60 mg subcutaneous injection every 6 months 1, 5
• Appropriate for high fracture risk or bisphosphonate intolerance 1
• Critical warning: Risk of multiple vertebral fractures upon discontinuation—requires transition to bisphosphonate if stopped 5
• Monitor for hypocalcemia, especially if renal impairment present 5

Raloxifene:

• Consider only in younger postmenopausal women with less severe osteoporosis 1
• Less appropriate at age 73 given weaker fracture data compared to bisphosphonates 1

Teriparatide:

• Reserved for severe osteoporosis with very high fracture risk or previous vertebral fractures 1, 3
• Not first-line at age 73 unless she has had fragility fractures 1

Monitoring and Follow-Up

Treatment monitoring schedule 6, 7:

• Repeat DXA in 1-2 years after starting treatment to assess response 7
• Minimum 2-year interval required to reliably detect bone density changes 6, 8
• Annual clinical assessment for adherence, side effects, and new fractures 7

Duration of Therapy and Drug Holidays

After 5 years of alendronate or 3 years of zoledronic acid 2:

• Consider drug holiday in patients at lower fracture risk 2
• Continue treatment if high fracture risk persists (T-score remains ≤ -2.5, previous fractures, or age >75 years) 2

Special Considerations for Age 73

This patient's age places her in a well-studied population with strong evidence for treatment benefit 1, 7:

• The mortality and morbidity benefits of hip fracture prevention are substantial at this age 2, 3
• Do not withhold treatment based on age—evidence supports treatment through the 70s and beyond 7
• While data is more limited beyond age 85, at 73 she falls squarely within evidence-based treatment guidelines 1, 7

Common Pitfalls to Avoid

• Do not delay treatment while optimizing calcium/vitamin D alone—start bisphosphonates concurrently 1
• Ensure adequate calcium and vitamin D before starting bisphosphonates to prevent hypocalcemia 5
• Screen for secondary causes of osteoporosis (hyperparathyroidism, vitamin D deficiency, celiac disease) if T-score is particularly low or unexpected 1
• Assess fall risk as falls are the proximate cause of most osteoporotic fractures 7
• Do not use calcitonin—it has weaker efficacy data and is no longer recommended as first-line therapy 1